Difference between revisions of "Alpha-methylacyl-CoA racemase"
Jump to navigation
Jump to search
| Line 4: | Line 4: | ||
*[[Prostate adenocarcinoma]].<ref name=pmid23376124>{{Cite journal | last1 = Lloyd | first1 = MD. | last2 = Yevglevskis | first2 = M. | last3 = Lee | first3 = GL. | last4 = Wood | first4 = PJ. | last5 = Threadgill | first5 = MD. | last6 = Woodman | first6 = TJ. | title = α-Methylacyl-CoA racemase (AMACR): metabolic enzyme, drug metabolizer and cancer marker P504S. | journal = Prog Lipid Res | volume = 52 | issue = 2 | pages = 220-30 | month = Apr | year = 2013 | doi = 10.1016/j.plipres.2013.01.001 | PMID = 23376124 }}</ref> | *[[Prostate adenocarcinoma]].<ref name=pmid23376124>{{Cite journal | last1 = Lloyd | first1 = MD. | last2 = Yevglevskis | first2 = M. | last3 = Lee | first3 = GL. | last4 = Wood | first4 = PJ. | last5 = Threadgill | first5 = MD. | last6 = Woodman | first6 = TJ. | title = α-Methylacyl-CoA racemase (AMACR): metabolic enzyme, drug metabolizer and cancer marker P504S. | journal = Prog Lipid Res | volume = 52 | issue = 2 | pages = 220-30 | month = Apr | year = 2013 | doi = 10.1016/j.plipres.2013.01.001 | PMID = 23376124 }}</ref> | ||
*[[Papillary renal cell carcinoma]].<Ref name=pmid16733210>{{Cite journal | last1 = Molinié | first1 = V. | last2 = Balaton | first2 = A. | last3 = Rotman | first3 = S. | last4 = Mansouri | first4 = D. | last5 = De Pinieux | first5 = I. | last6 = Homsi | first6 = T. | last7 = Guillou | first7 = L. | title = Alpha-methyl CoA racemase expression in renal cell carcinomas. | journal = Hum Pathol | volume = 37 | issue = 6 | pages = 698-703 | month = Jun | year = 2006 | doi = 10.1016/j.humpath.2006.01.012 | PMID = 16733210 }}</ref> | *[[Papillary renal cell carcinoma]].<Ref name=pmid16733210>{{Cite journal | last1 = Molinié | first1 = V. | last2 = Balaton | first2 = A. | last3 = Rotman | first3 = S. | last4 = Mansouri | first4 = D. | last5 = De Pinieux | first5 = I. | last6 = Homsi | first6 = T. | last7 = Guillou | first7 = L. | title = Alpha-methyl CoA racemase expression in renal cell carcinomas. | journal = Hum Pathol | volume = 37 | issue = 6 | pages = 698-703 | month = Jun | year = 2006 | doi = 10.1016/j.humpath.2006.01.012 | PMID = 16733210 }}</ref> | ||
*[[High-grade prostatic intraepithelial neoplasia]]. | |||
==Positive or negative== | ==Positive or negative== | ||
Revision as of 16:38, 11 December 2014
Alpha-methylacyl-CoA racemase, abbreviated AMACR, is a commonly used immunostain in genitourinary pathology.
Positive
- Prostate adenocarcinoma.[1]
- Papillary renal cell carcinoma.[2]
- High-grade prostatic intraepithelial neoplasia.
Positive or negative
- Nephrogenic adenoma.
- Urothelial carcinoma - not useful for differentating prostate versus bladder.
Negative
See also
References
- ↑ Lloyd, MD.; Yevglevskis, M.; Lee, GL.; Wood, PJ.; Threadgill, MD.; Woodman, TJ. (Apr 2013). "α-Methylacyl-CoA racemase (AMACR): metabolic enzyme, drug metabolizer and cancer marker P504S.". Prog Lipid Res 52 (2): 220-30. doi:10.1016/j.plipres.2013.01.001. PMID 23376124.
- ↑ Molinié, V.; Balaton, A.; Rotman, S.; Mansouri, D.; De Pinieux, I.; Homsi, T.; Guillou, L. (Jun 2006). "Alpha-methyl CoA racemase expression in renal cell carcinomas.". Hum Pathol 37 (6): 698-703. doi:10.1016/j.humpath.2006.01.012. PMID 16733210.